vs
Side-by-side financial comparison of CENTRAL PACIFIC FINANCIAL CORP (CPF) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
CENTRAL PACIFIC FINANCIAL CORP is the larger business by last-quarter revenue ($72.9M vs $57.6M, roughly 1.3× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 6.0%).
Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
CPF vs PHAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.9M | $57.6M |
| Net Profit | $20.7M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | — | — |
| Net Margin | 28.4% | — |
| Revenue YoY | 6.0% | 94.1% |
| Net Profit YoY | 16.7% | 71.6% |
| EPS (diluted) | $0.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $76.3M | $57.6M | ||
| Q3 25 | $74.8M | $49.5M | ||
| Q2 25 | $72.8M | $39.5M | ||
| Q1 25 | $68.8M | $28.5M | ||
| Q4 24 | $58.4M | $29.7M | ||
| Q3 24 | $66.6M | $16.4M | ||
| Q2 24 | $64.0M | $7.3M |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $22.9M | — | ||
| Q3 25 | $18.6M | $-30.0M | ||
| Q2 25 | $18.3M | $-75.8M | ||
| Q1 25 | $17.8M | $-94.3M | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $13.3M | $-85.6M | ||
| Q2 24 | $15.8M | $-91.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% |
| Q1 26 | — | — | ||
| Q4 25 | 37.0% | — | ||
| Q3 25 | 31.6% | -30.8% | ||
| Q2 25 | 32.8% | -151.7% | ||
| Q1 25 | 32.8% | -276.5% | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 25.6% | -433.0% | ||
| Q2 24 | 32.2% | -1055.4% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 30.0% | — | ||
| Q3 25 | 24.8% | -60.5% | ||
| Q2 25 | 25.1% | -191.9% | ||
| Q1 25 | 25.8% | -330.7% | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 20.0% | -523.3% | ||
| Q2 24 | 24.7% | -1248.6% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.85 | — | ||
| Q3 25 | $0.69 | $-0.41 | ||
| Q2 25 | $0.67 | $-1.05 | ||
| Q1 25 | $0.65 | $-1.31 | ||
| Q4 24 | $0.42 | — | ||
| Q3 24 | $0.49 | $-1.32 | ||
| Q2 24 | $0.58 | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $130.0M |
| Total DebtLower is stronger | $76.5M | $209.1M |
| Stockholders' EquityBook value | $593.9M | $-438.2M |
| Total Assets | $7.5B | $259.1M |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | — | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | — | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | — | $276.2M |
| Q1 26 | $76.5M | — | ||
| Q4 25 | $76.5M | $209.1M | ||
| Q3 25 | $131.5M | $207.1M | ||
| Q2 25 | $131.5M | $205.1M | ||
| Q1 25 | $131.4M | $203.2M | ||
| Q4 24 | $156.3M | $201.4M | ||
| Q3 24 | $156.3M | $175.7M | ||
| Q2 24 | $156.2M | $174.4M |
| Q1 26 | $593.9M | — | ||
| Q4 25 | $592.6M | $-438.2M | ||
| Q3 25 | $588.1M | $-422.5M | ||
| Q2 25 | $568.9M | $-405.8M | ||
| Q1 25 | $557.4M | $-338.4M | ||
| Q4 24 | $538.4M | $-253.6M | ||
| Q3 24 | $543.7M | $-187.1M | ||
| Q2 24 | $518.6M | $-233.8M |
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.4B | $259.1M | ||
| Q3 25 | $7.4B | $240.3M | ||
| Q2 25 | $7.4B | $250.2M | ||
| Q1 25 | $7.4B | $294.2M | ||
| Q4 24 | $7.5B | $378.3M | ||
| Q3 24 | $7.4B | $387.0M | ||
| Q2 24 | $7.4B | $319.4M |
| Q1 26 | 0.13× | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | $-166.8M | ||
| Q3 25 | $22.2M | $-14.1M | ||
| Q2 25 | $34.3M | $-62.7M | ||
| Q1 25 | $20.4M | $-84.9M | ||
| Q4 24 | $90.5M | $-266.8M | ||
| Q3 24 | $21.3M | $-63.6M | ||
| Q2 24 | $25.9M | $-70.7M |
| Q1 26 | — | — | ||
| Q4 25 | $92.3M | $-167.0M | ||
| Q3 25 | $21.4M | $-14.1M | ||
| Q2 25 | $32.3M | $-62.8M | ||
| Q1 25 | $19.6M | $-84.9M | ||
| Q4 24 | $75.4M | $-266.9M | ||
| Q3 24 | $15.6M | $-63.6M | ||
| Q2 24 | $21.3M | $-70.8M |
| Q1 26 | — | — | ||
| Q4 25 | 121.0% | -290.0% | ||
| Q3 25 | 28.6% | -28.6% | ||
| Q2 25 | 44.3% | -159.0% | ||
| Q1 25 | 28.4% | -297.9% | ||
| Q4 24 | 129.2% | -899.8% | ||
| Q3 24 | 23.5% | -389.0% | ||
| Q2 24 | 33.2% | -966.2% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 0.4% | ||
| Q3 25 | 1.2% | 0.1% | ||
| Q2 25 | 2.7% | 0.2% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 25.8% | 0.5% | ||
| Q3 24 | 8.5% | 0.3% | ||
| Q2 24 | 7.3% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 7.98× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
